Standout Papers
Citation Impact
Citing Papers
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment
2018
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Cancer statistics, 2022
2022 Standout
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2017
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
2018 StandoutNobel
Cancer statistics, 2020
2020 Standout
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Cancer Statistics, 2021
2021 Standout
Engineering precision nanoparticles for drug delivery
2020 Standout
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
2017
Determining cell type abundance and expression from bulk tissues with digital cytometry
2019 Standout
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
2019 Standout
An Acquired and Endogenous Glycocalyx Forms a Bidirectional “Don’t Eat” and “Don’t Eat Me” Barrier to Phagocytosis
2020 StandoutNobel
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
2021
Phagocytosis checkpoints as new targets for cancer immunotherapy
2019
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
2018
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
2016
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Transforming Growth Factor-β Signaling in Immunity and Cancer
2019 Standout
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?
2017
Guillain-Barré syndrome
2016 Standout
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
2017
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
2017 Nature
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment
2018
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
Improving cancer immunotherapy through nanotechnology
2019
Lung cancer: current therapies and new targeted treatments
2016 Standout
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Synthetic lethality as an engine for cancer drug target discovery
2019
Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?
2018
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
2018
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
2017
Current state of immunotherapy for non-small cell lung cancer
2007
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Sarcopenia
2019 Standout
Phenotype molding of stromal cells in the lung tumor microenvironment
2018
Tumour burden and efficacy of immune-checkpoint inhibitors
2021
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
2017
Immune checkpoint inhibitors: recent progress and potential biomarkers
2018 Standout
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells
2020
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
2018
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
2017
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Integrin αvβ8–expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells
2018
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
2017
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
2018
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
2018
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
2018 Standout
Hyperprogressive disease: recognizing a novel pattern to improve patient management
2018
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Immune checkpoint inhibitors: new strategies to checkmate cancer
2017
Regulatory T Cells and Human Disease
2020 StandoutNobel
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
2020
Targeting ALK: Precision Medicine Takes on Drug Resistance
2017
New insights into the role of EMT in tumor immune escape
2017
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
2017 Standout
Regulation of brachyury by fibroblast growth factor receptor 1 in lung cancer
2016
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
The global burden of lung cancer: current status and future trends
2023
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Metabolic reprogramming and cancer progression
2020 StandoutScience
Cancer statistics, 2015
2015 Standout
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update
2017
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
2017 StandoutNobel
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Emerging role of extracellular vesicles in mediating cancer cachexia
2018
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Engineering nanoparticles to locally activate T cells in the tumor microenvironment
2019
The National Lung Screening Trial: Results stratified by demographics, smoking history, and lung cancer histology
2013
Works of Sinéad Cuffe being referenced
Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers
2011
Vaping and lung cancer – A review of current data and recommendations
2021
A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit From Adjuvant Platinum-Based Chemotherapy in Node-Negative Non–Small Cell Lung Cancer
2012
Targeting the fibroblast growth factor receptor family in cancer
2016
The emerging role of microRNAs in resistance to lung cancer treatments
2014
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
2017
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.
2017
3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial
2015
OA 17.06 Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%
2017